• 1.四川大學(xué)華西醫(yī)院普外科(成都610041);;
  • 2.內(nèi)蒙古包頭市腫瘤醫(yī)院(包頭014000);;
  • 通訊作者: 伍曉汀;

目的研究胃癌增殖細胞核抗原(proliferating cell nuclear antigen,PCNA)表達與腹腔灌洗液端粒酶活性及腹膜轉(zhuǎn)移的相關(guān)性,并比較腹腔灌洗液中端粒酶活性和細胞學(xué)檢測游離癌細胞預(yù)測腹膜轉(zhuǎn)移的應(yīng)用價值。
方法應(yīng)用免疫組化SP法檢測60例胃癌患者胃癌組織中PCNA表達,PCRTRAPELISA法檢測腹腔灌洗液中端粒酶活性,同時行腹腔灌洗液脫落細胞學(xué)(peritoneal lavage cytology,PLC)檢測; 并分析其與相關(guān)臨床病理因素的關(guān)系。
結(jié)果胃癌患者腹腔灌洗液中端粒酶活性的陽性率為41.7%; 與漿膜侵犯、組織學(xué)類型、浸潤深度、漿膜受累面積及腹膜轉(zhuǎn)移密切相關(guān),并隨著浸潤深度及漿膜受累面積的增加而升高(P<0.05)。PLC檢測陽性率為25.0%; 在伴肉眼可見腹膜轉(zhuǎn)移灶(P1~3)者明顯增高,也隨著浸潤深度及漿膜受累面積的增加而升高。兩種方法檢測的陽性率總體上差異無統(tǒng)計學(xué)意義,但在未分化型癌、pT4、伴肉眼可見腹膜轉(zhuǎn)移灶(P1~3)者端粒酶活性陽性率明顯高于PLC。PCNA增殖指數(shù)(PI)在腹腔灌洗液端粒酶活性表達陽性者明顯高于表達陰性者,伴肉眼可見腹膜轉(zhuǎn)移灶(P1~3)者明顯高于無肉眼可見腹膜轉(zhuǎn)移灶(P0)者,漿膜受侵者明顯高于漿膜未受侵者(P均<0.05)。
結(jié)論兩種方法均適用于胃癌腹腔脫落癌細胞的診斷或腹膜轉(zhuǎn)移的預(yù)測,端粒酶活性檢測微量癌細胞的靈敏度優(yōu)于PLC法檢測; 胃癌端粒酶活性與惡性增殖活性密切相關(guān); 胃癌高增殖活性是漿膜受侵及腹膜轉(zhuǎn)移的重要原因。

引用本文: 達明緒 ,趙紫罡,羅婷,張明鳴,伍曉汀. 胃癌細胞增殖與腹腔灌洗液中端粒酶活性及腹膜轉(zhuǎn)移的相關(guān)性研究. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(1): 25-28. doi: 復(fù)制

1. Lee CC, Lo SS, Wu CW, et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection [J]. Hepatogastroenterology, 2003; 50(53)∶1720.
2. Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome [J]. J Surg Oncol, 1995; 59(4)∶226.
3. Asao T, Fukuda T, Yazawa S, et al. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer [J]. Cancer, 1991; 68(1)∶44.
4. Bonenkamp JJ, Songun I, Hermans J, et al. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer [J]. Br J Surg, 1996; 83(5)∶672.
5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [J]. Eur J Cancer, 1997; 33(5)∶787.
6. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer [J]. Cancer Res, 1995; 55(15)∶3258.
7. Maruyama Y, Hanai H, Fujita M, et al. Telomere length and telomerase activity in carcinogenesis of the stomach [J]. Jpn J Clin Oncol, 1997; 27(4)∶216.
8. Ahn MJ, Noh YH, Lee YS, et al. Telomerase activity and its clinicopathological significance in gastric cancer [J]. Eur J Cancer, 1997; 33(8)∶1309.
  1. 1. Lee CC, Lo SS, Wu CW, et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection [J]. Hepatogastroenterology, 2003; 50(53)∶1720.
  2. 2. Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome [J]. J Surg Oncol, 1995; 59(4)∶226.
  3. 3. Asao T, Fukuda T, Yazawa S, et al. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer [J]. Cancer, 1991; 68(1)∶44.
  4. 4. Bonenkamp JJ, Songun I, Hermans J, et al. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer [J]. Br J Surg, 1996; 83(5)∶672.
  5. 5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [J]. Eur J Cancer, 1997; 33(5)∶787.
  6. 6. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer [J]. Cancer Res, 1995; 55(15)∶3258.
  7. 7. Maruyama Y, Hanai H, Fujita M, et al. Telomere length and telomerase activity in carcinogenesis of the stomach [J]. Jpn J Clin Oncol, 1997; 27(4)∶216.
  8. 8. Ahn MJ, Noh YH, Lee YS, et al. Telomerase activity and its clinicopathological significance in gastric cancer [J]. Eur J Cancer, 1997; 33(8)∶1309.